Show simple item record

dc.contributor.authorMeyer, T
dc.contributor.authorFinn, R
dc.contributor.authorKudo, M
dc.contributor.authorKang, Y
dc.contributor.authorYen, C
dc.contributor.authorGalle, P
dc.contributor.authorLlovet, J
dc.contributor.authorAssenat, E
dc.contributor.authorBrandi, G
dc.contributor.authorMotomura, K
dc.contributor.authorOkusaka, T
dc.contributor.authorHubner, Richard A
dc.contributor.authorKarwal, M
dc.contributor.authorBaron, A
dc.contributor.authorIkeda, M
dc.contributor.authorLiang, K
dc.contributor.authorWang, C
dc.contributor.authorWidau, R
dc.contributor.authorSchelman, W
dc.contributor.authorZhu, A
dc.date.accessioned2020-03-27T09:28:03Z
dc.date.available2020-03-27T09:28:03Z
dc.date.issued2019en
dc.identifier.citationMeyer T, Finn R, Kudo M, Kang Y, Yen C, Galle P, et al. Ramucirumab in advanced hepatocellular carcinoma and elevated alpha-fetoprotein following sorafenib: outcomes by prior transarterial chemoembolisation from two randomised, double-blind, placebo-controlled phase 3 studies (REACH-2 and REACH). Ann Oncol. 2019;30 Suppl 4:iv133.en
dc.identifier.pmid32085038en
dc.identifier.doi10.1093/annonc/mdz154.020en
dc.identifier.urihttp://hdl.handle.net/10541/622839
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1093/annonc/mdz154.020en
dc.titleRamucirumab in advanced hepatocellular carcinoma and elevated alpha-fetoprotein following sorafenib: outcomes by prior transarterial chemoembolisation from two randomised, double-blind, placebo-controlled phase 3 studies (REACH-2 and REACH)en
dc.typeMeetings and Proceedingsen
dc.contributor.departmentRoyal Free Hospital, University College London, London, UKen
dc.identifier.journalAnnals of Oncologyen
dc.description.noteen]
refterms.dateFOA2020-03-30T14:03:38Z


Files in this item

Thumbnail
Name:
32085038.pdf
Size:
89.16Kb
Format:
PDF
Description:
From UNPAYWALL

This item appears in the following Collection(s)

Show simple item record